Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 19/20 | 1.00 |
| ▸ | THRA | P10827 | 18/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898278 | 0.99 | THRB (0.97) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL4900725 | 0.85 | THRB (1.00) | THRBTHRAS1PR2S1PR1S1PR3 | |
| SCHEMBL20527124 | 0.84 | THRA (0.72) | THRBTHRA | |
| SCHEMBL4899221 | 0.84 | THRB (1.00) | THRBTHRAS1PR2S1PR1S1PR3 | |
| SCHEMBL1066946 | 0.83 | THRA (0.71) | THRBTHRAS1PR1S1PR3 | |
| SCHEMBL4895853 | 0.80 | THRA (1.00) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL4890007 | 0.79 | THRB (1.00) | THRBTHRAS1PR2S1PR1S1PR3 | |
| SCHEMBL4894303 | 0.79 | THRB (0.65) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL4900338 | 0.78 | THRA (0.68) | THRBTHRAESR1NR3C1PGR | |
| SCHEMBL19193897 | 0.78 | THRA (0.63) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | THRB 792/4885THRA 559/4885ESR1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.